Search

Your search keyword '"Besses C"' showing total 408 results

Search Constraints

Start Over You searched for: Author "Besses C" Remove constraint Author: "Besses C"
408 results on '"Besses C"'

Search Results

1. miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk

3. Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)

17. Fourth meeting of the European Neurological Society 25–29 June 1994 Barcelona, Spain: Abstracts of Symposia and free communications

19. A randomized multicentric study comparing alternating combination chemotherapy (VCMP/VBAP) and melphalan-prednisone in multiple myeloma

20. Essential thrombocythaemia with mutation in MPL : clinicopathological correlation and comparison with JAK 2V617F-mutated and CALR- mutated genotypes

21. Essential thrombocythaemia with mutation in MPL: clinicopathological correlation and comparison with JAK2V617F-mutated and CALR-mutated genotypes

27. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea

30. LEUKEMIC TRANSFORMATION AND SECOND CANCERS IN 3649 HIGH RISK ET PATIENTS IN THE EXELS STUDY

32. Molecular characterisation of triple negative essential thrombocythaemia patients by platelet analysis and targeted sequencing

35. Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia

36. SYMPTOMS, RISK CLASSIFICATION, AND SPLEEN SIZE IN JAK2 INHIBITOR-NAIVE MYELOFIBROSIS : IMPLICATIONS FOR JAK2 INHIBITOR TREATMENT

37. Development Of An Mf Patient Reported Outcome (Pro) Tool For Fda Qualification : Comprehensive Literature Search And Physician Cognitive Debriefing Results

39. Impact Of Splenomegaly On Mpn Symptoms And Association With Clinical Features : An Analysis By The Mpn Quality Of Life International Study Group

41. Treatment of high risk ET : data from the EXELS study

42. Indirect and non-medical economic burden, quality-of-life, and disabilities of the myelofibrosis disease in Spain

43. The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis

44. JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events

45. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea

47. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation

49. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial

Catalog

Books, media, physical & digital resources